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Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care
(SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a
multi-arm multi-stage platform randomised controlled protocol recruiting patients with high-risk locally advanced or metastatic
PCa starting long-term androgen deprivation therapy (ADT). The protocol provides the only direct, randomised comparative
data of SOCþAAP versus SOCþDocP.
Method: Recruitment to SOCþDocP and SOCþAAP overlapped November 2011 to March 2013. SOC was long-term ADT or,
for most non-metastatic cases, ADT for2 years and RT to the primary tumour. Stratified randomisation allocated pts 2 : 1 : 2 to
SOC; SOCþ docetaxel 75mg/m2 3-weekly6þ prednisolone 10mg daily; or SOCþ abiraterone acetate
1000mgþprednisolone 5mg daily. AAP duration depended on stage and intent to give radical RT. The primary outcome
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measure was death from any cause. Analyses used Cox proportional hazards and flexible parametric models, adjusted for
stratification factors. This was not a formally powered comparison. A hazard ratio (HR)<1 favours SOCþAAP, and HR> 1
favours SOCþDocP.
Results: A total of 566 consenting patients were contemporaneously randomised: 189 SOCþDocP and 377 SOCþAAP. The
patients, balanced by allocated treatment were: 342 (60%) M1; 429 (76%) Gleason 8–10; 449 (79%) WHO performance status 0;
median age 66 years and median PSA 56 ng/ml. With median follow-up 4 years, 149 deaths were reported. For overall survival,
HR¼ 1.16 (95% CI 0.82–1.65); failure-free survival HR¼ 0.51 (95% CI 0.39–0.67); progression-free survival HR¼ 0.65 (95% CI 0.48–
0.88); metastasis-free survival HR¼ 0.77 (95% CI 0.57–1.03); prostate cancer-specific survival HR¼ 1.02 (0.70–1.49); and
symptomatic skeletal events HR¼ 0.83 (95% CI 0.55–1.25). In the safety population, the proportion reporting1 grade 3, 4 or 5
adverse events ever was 36%, 13% and 1% SOCþDocP, and 40%, 7% and 1% SOCþAAP; prevalence 11% at 1 and 2 years on
both arms. Relapse treatment patterns varied by arm.
Conclusions: This direct, randomised comparative analysis of two new treatment standards for hormone-naı¨ve prostate cancer
showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as
symptomatic skeletal events. Worst toxicity grade over entire time on trial was similar but comprised different toxicities in line
with the known properties of the drugs.
Trial registration: Clinicaltrials.gov: NCT00268476.
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Research in context
Evidence before this study
Abiraterone acetate plus prednisone/prednisolone (AAP) and
docetaxel with prednisone/prednisolone (DocP) have separately
been shown to improve survival when used in addition to the pre-
vious international standard-of-care (SOC) for hormone-
sensitive prostate cancer of androgen deprivation therapy with
further therapy such as AAP or DocP on relapse. This has been
confirmed in a number of separate trials and on meta-analysis.
The largest body of evidence for both AAP and DocP comes from
the systemic therapy for advanced or metastatic prostate cancer:
evaluation of drug efficacy (STAMPEDE) platform trial.
Added value of this study
Recruitment to DocP and AAP overlapped in STAMPEDE giving
the only head-to-head evidence comparing these two new stand-
ard treatment approaches. We report data from the 566 patients
who were directly randomised between these two treatment
approaches while the two research arms were both open to re-
cruitment. The data show strong evidence favouring SOCþAAP
on earlier, more biochemically driven outcome measures (OMs).
For longer-term, more clinically driven OMs, including bone
complications, prostate cancer-specific and overall survival, there
is no evidence of a significant difference between AAP and DocP.
Implications of all the available evidence
The reported trials and meta-analyses showed a larger effect on sur-
vival for AAP over the previous SOC than did DocP over the stand-
ard SOC. These data show that the story may be more
complicated. No other directly randomised data on survival of
these treatments are available. Individual patient data network
meta-analysis using all of the published trials are warranted, ac-
counting for differences in patient characteristics, treating clin-
icians and centres and salvage treatment access. The STAMPEDE
team is collaborating with the STOPCAP meta-analysis group to
achieve this.
Introduction
For several decades, the standard-of-care (SOC) for most patients
with high-risk locally advanced or metastatic prostate cancer has
been long-term androgen deprivation therapy (ADT) alone. The
past few years, there have been great changes, first with results
from randomised controlled trials (RCTs) showing a survival ad-
vantage compared with ADT alone for adding radiotherapy to
the prostate in men with non-metastatic disease and no known
nodal involvement [1–3]; then with systemic treatments for all
men starting long-term hormone therapy: docetaxel plus pred-
nisolone/prednisone (DocP) [4–9] and, most recently, abirater-
one acetate plus prednisolone/prednisone (AAP) [10, 11]. As
both therapeutic combinations are effective, there are now two
distinct standards-of-care with little information to guide clin-
icians as to which is the more effective; there are no prospective,
powered, RCTs that will deliver direct comparative data.
Systemic therapy for advanced or metastatic prostate cancer:
evaluation of drug efficacy (STAMPEDE) is a multi-arm, multi-
stage platform protocol which assessed both of these treatment
approaches, separately, against the previous SOC [12, 13]. The
‘docetaxel comparison’ of STAMPEDE recruited patients allo-
cated to SOCþDocP between October 2005 and March 2013.
The ‘abiraterone comparison’, the first comparison to be added
to STAMPEDE, recruited patients allocated to SOC or
SOCþAAP between November 2011 and January 2014. Each of
those comparisons had primary outcome measure (OM) of over-
all survival (OS) for the patients randomised contemporaneously
to the control arm and the relevant research arm. Consequently,
between 15 November 2011 and 31 March 2013, patients were
directly randomised contemporaneously between these two re-
search arms (and other research arms) and we now present these
data.
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Methods
Trial design
The STAMPEDE protocol and design have been described in detail else-
where [7, 10, 12, 14]. Briefly, STAMPEDE comprises a series of multi-
arm multi-stage (MAMS) comparisons that have overlapped in recruit-
ment and follow-up time.
Patient selection
Eligible patients were those starting long-term ADT for the first time.
This was defined as patients with metastatic disease, nodal involvement
or node negative, non-metastatic disease with two or more of three high-
risk features: T-category 3 or 4, Gleason sum score 8–10 or PSA > 40 ng/
ml. Patients rapidly relapsing after previous local therapy were also per-
mitted if they had PSA> 20 ng/ml or PSA> 4 ng/ml with a PSA doubling
time<6 months or those who developed loco-regional or metastatic
spread whilst not on hormone therapy.
As with all STAMPEDE comparisons, the primary OM of the two
underpinning comparisons (against control) was OS. Failure-free sur-
vival (FFS) was an intermediate primary OM, defined as time from ran-
domisation to the first of: rising PSA (where rising PSA was defined as a
confirmed rise to>4 ng/ml, and>50% above the lowest value in the first
6 months after randomisation); new disease or progression of: distant
metastases, lymph nodes or local disease; or death from prostate cancer.
Progression-free survival (PFS) was defined as time from randomisation
to the first of: new disease or progression of: distant metastases, lymph
nodes or local disease; or death from prostate cancer [15]. Metastatic PFS
(MPFS) was defined as time from randomisation to death from any
cause, new metastases or progression of distant metastases.
All patients provided written informed consent; all versions of the
protocol have been reviewed by the relevant research ethics committees
and the regulatory agencies; the original protocol and all subsequent ver-
sions involving the introduction of a new research arm and comparison
were independently peer-reviewed by Cancer Research UK (CRUK).
Patients have been allocated across a number of research treatments as
depicted in Figure 1. Here we focus on those patients randomised be-
tween 15 November 2011 and 31 March 2013, while both the ‘docetaxel
comparison’ and the ‘abiraterone comparison’ were open to recruitment,
and who were allocated to either SOCþDocP or SOCþAAP.
Trial treatment, masking and follow-up
The SOC was long-term hormone therapy with LHRH analogues (with
short term antiandrogen if relevant) or orchidectomy. Unless contraindi-
cated, radiotherapy to the prostate was mandated in all patients with
N0M0 disease, encouraged in patient with NþM0 disease, and permit-
ted in patients with M1 disease until the activation of the ‘M1jRT com-
parison’ in January 2013. On the DocP arm, docetaxel (75 mg/m2) was
given once every 3 weeks for six cycles, with prednisolone/prednisone
(10 mg) daily. On the AAP arm, abiraterone acetate (1000 mg) with pred-
nisolone/prednisone (5 mg) daily was given until PSA, clinical and radio-
logical progression or a change of treatment. AAP duration was capped
after 2 years in M0 patients having radical radiotherapy. Modifications
for toxicities were described in the protocol and previous papers [7, 10].
Treatment allocation was not masked for practical reasons. Patients were
seen 6-weekly at first, dropping to 6-monthly after 2 years. Imaging scans
after baseline were at the investigator’s discretion.
Randomisation
Patients were randomised centrally using minimisation with a random
element across a number of stratification factors using unequal allocation
(previously described) [7, 10]. The allocation ratio was initially 2 : 1 con-
trol : research; the ‘abiraterone comparison’ was brought in with an equal
allocation (1 : 1) ratio to the control. Therefore the allocation ratio here is
1 : 2 for SOCþDocP : SOCþAAP.
Statistical analysis
The comparison presented here is of SOCþAAP against SOCþDocP
because both of these arms have demonstrated better OS than their con-
temporaneous controls in the population of men starting long-term hor-
mone therapy. The protocol specified that research arms which were
better than the control arm could be compared, following a closed test
approach. The maturity of the data used for SOCþAAP matches that re-
cently reported [10] in the primary results and is updated to the same
data freeze timepoint for SOCþDocP so is longer-term data than previ-
ously reported results for this arm [7].
The previously-reported comparisons of SOCþDocP versus SOC and
SOCþAAP versus SOC had formal sample size calculations; there is no
formal sample size calculation for this comparison: it is an opportunistic
comparison between the contemporaneously recruited research arm pa-
tients. Although the recruitment overlap is only 17 months, 566 patients
were allocated to the 2 research arms of interest and thus contribute sub-
stantial information to inform this comparison.
Standard survival analysis methods were used, following the approach
for each of these underpinning comparisons; hazard ratios (HR) were
estimated from adjusted Cox models, after checking that the propor-
tional hazards assumption held, where an HR < 1 represents evidence in
favour of SOCþAAP and HR> 1 represents evidence in favour of
SOCþDocP. Nominal confidence intervals are presented at the 95%
level. A P-value<0.1 was considered indicative of treatment-baseline
characteristic interaction, recognising the limited power of the hetero-
geneity tests. Efficacy analyses were done in the intention-to-treatment
basis, by allocated treatment. Safety analyses were done only in patients
who started their allocated treatment.
Results
Accrual and characteristics
The dataset for this comparison was frozen on 10 February 2017.
Between 15 November 2011 and 31 March 2013, 1348 patients
joined all open arms STAMPEDE. Of the 566 randomised to the
comparison reported here, 189 (14%) were allocated to
SOCþDocP, 377 (28%) to SOCþAAP. The flow of patients to
this comparison is shown in Figure 2. Table 1 shows the baseline
characteristics of patients in this comparison which differ only
slightly from the previous papers (summarised in supplementary
Table S1, available at Annals of Oncology online). Median follow-
up, calculated by reverse censoring on survival, was 48 months.
Overall survival
There were 44/189 (23%) deaths on the SOCþDocP arm and
105/377 (28%) deaths on the SOCþAAP arm. The estimated
HR¼ 1.16 (95% CI 0.82–1.65; P¼ 0.40) (Figure 3A). Estimates
in patients with and without metastases are shown in Table 2,
with HR¼ 1.51 (95% CI 0.58–3.93) in M0 patients and
HR¼ 1.13 (95% CI 0.77–1.66) in M1 patients. There was no evi-
dence of interaction in the treatment effect by baseline metastases
(P¼ 0.69).
Totally, 126/149 deaths were attributed to prostate cancer,
comprising 10/22 and 116/127 deaths in patients with M0 and
M1 disease at entry, respectively. Competing risks regression
shows no evidence of a difference in prostate cancer-specific
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Table 1. Baseline characteristics of patients allocated to SOC1 DocP or SOC1 AAP by whether contributing to the direct comparison
SOC1DocP SOC1AAP Overall
Characteristic N % N % N %
Metastases
M0 74 39 150 40 224 40
M1 115 61 227 60 342 60
Nodal stage
N0 82 43 158 42 240 44
Nþ 99 52 202 53 301 56
NX 8 4 17 5 25 n/a
Combination
N0 M0 43 23 84 22 127 22
NþM0 31 16 66 18 97 17
N0 M1 39 21 74 20 113 20
Nþ M1 68 36 136 36 204 36
NX M1 8 4 17 5 25 4
Tumour category
<T3 24 13 36 10 60 11
T3 123 65 249 66 372 69
T4 39 20 68 18 107 20
Tx 3 2 24 6 27 n/a
Gleason category
7 35 19 91 25 126 23
8–10 153 81 276 75 429 76
Unknown 1 — 10 — 11 n/a
Previous local therapy
No 183 97 350 93 533 94
Yes 6 3 27 7 33 6
WHO performance status
0 149 79 300 80 449 79
1–2 40 21 77 20 117 21
Age (years)
<70 134 71 267 71 401 71
70þ 55 29 110 29 165 29
Median (quartiles) 66 (62–71) 66 (61–70) 66 (62–70)
Mean (SD) 66 (7) 66 (7) 66 (7)
Use of NSAID or aspirin
No use 141 75 280 74 421 74
Uses either 48 25 97 26 145 26
PSA (ng/ml)
Median (quartiles) 58 (29–162) 55 (20–194) 56 (22–185)
Mean (SD) 193 (421) 274 (631) 247 (571)
Ln PSA (ng/ml)
Median (quartiles) 4.1 (3.4–5.1) 4.0 (3.0–5.3) 4.0 (3.1–5.2)
Mean (SD) 4.2 (1.4) 4.2 (1.6) 4.2 (1.5)
RT planned
M0, yes 57 77 118 79 175 78
M0, no 17 23 32 21 49 22
M1, yes 12 10 21 9 33 10
M1, no 103 89 206 91 309 90
Hypertension
Yes (still ﬁt for trial) 64 34 149 40 213 38
No 125 66 227 60 352 62
Year of randomisation
2011 15 8 27 7 42 7
2012 138 73 277 73 415 73
2013 36 19 73 19 109 19
Annals of Oncology Original article
Volume 29 | Issue 5 | 2018 doi:10.1093/annonc/mdy072 | 1239
survival (sub-HR¼ 1.02, 95% CI 0.70–1.49). For non-prostate
cancer-specific survival, with 23/149 deaths attributed to other
causes, the sub-HR was 2.33 (95% CI 0.78–6.99). There was no
evidence of heterogeneity of treatment effect by baseline metasta-
ses in either outcome.
Other efficacy OMs
Table 2 shows the effect size overall and by whether the patients
had metastases at entry for FFS, PFS, MPFS and skeletal-related
events. There is no evidence of heterogeneity of the treatment
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effect by baseline metastases in any of these OMs. Figure 4 sum-
marises the effect for all OMs.
Safety
The safety population includes people who started their allocated
treatment. While nearly all patients allocated to AAP started it, a
proportion of those patients allocated to receive docetaxel
declined to start it. Table 3 summarises the worst toxicity re-
ported for patients over their time on trial in the safety popula-
tion and shows differing patterns for adverse events according to
treatment. The prevalence of grade 3 or 4 toxicity in patients with
assessments at 1 year without a prior FFS event was 11%
SOCþDocP and 11% SOCþAAP; at 2 years this was 11%
SOCþDocP and 11% SOCþAAP.
Second-line treatment
Figure 5 shows time from randomisation to any subsequent
exposure to docetaxel or AR-targeted therapy with AAP or
enzalutamide. Figure 6 shows time from an FFS event to re-
ported exposure to selected treatments that are licensed for
CRPC: docetaxel, AAP, enzalutamide. There was limited re-
ported use of cabazitaxel, radium and sipuleucel-T at this
point (not shown).
Table 2. Hazard ratio for SOC1 AAP relative to SOC1 DocP from adjusted Cox models
Outcome
measure
Patient
group
Events/Pts
SOC1DocP
Events/Pts
SOC1AAP
Hazard ratioa
(95% CI)
P-value Interaction by
metastases P-value
Failure-free survivalb
All 97/189 122/377 0.51 (0.39–0.67) <0.001
M0 18/74 13/150 0.34 (0.16–0.69) 0.003
M1 79/115 109/227 0.56 (0.42–0.75) <0.001 0.169
Progression-free survivalb
All 72/189 103/377 0.65 (0.48–0.88) 0.005
M0 10/74 9/150 0.42 (0.17–1.05) 0.064
M1 62/115 94/227 0.69 (0.50–0.95) 0.023 0.323
Metastatic progression-free survivalc
All 71/189 118/377 0.77 (0.57–1.03) 0.079
M0 10/74 18/150 0.91 (0.42–2.01) 0.824
M1 61/115 100/227 0.76 (0.55–1.04) 0.085 0.744
Freedom from symptomatic skeletal events
All 36/189 63/377 0.83 (0.55–1.25) 0.375
M0 2/74 5/150 1.28 (0.24–6.67) 0.771
M1 34/115 58/227 0.82 (0.53–1.25) 0.351 0.648
Overall survival
All 44/189 105/377 1.16 (0.82–1.65) 0.404
M0 6/74 16/150 1.51 (0.58–3.93) 0.395
M1 38/115 89/227 1.13 (0.77–1.66) 0.528 0.691
Outcome
measure
Patient
group
Events/Pts
SOC1Doc
Events/Pts
SOC1AAP
Sub-hazard ratiod
(95% CI)
P-value Interaction by
metastases P-value
Death from prostate cancere
All 40/189 86/377 1.02 (0.70–1.49) 0.916
M0 4/74 6/150 0.82 (0.24–2.81) 0.751
M1 36/115 80/227 1.05 (0.71–1.56) 0.807 0.620
Death from other causesf
All 4/189 19/377 2.33 (0.77–6.99) 0.131
M0 2/74 10/150 3.00 (0.66–13.66) 0.155
M1 2/115 9/227 1.91 (0.43–8.41) 0.393 0.771
aFrom Cox proportional hazards model, adjusted for stratiﬁcation factors at randomisation (except hospital and choice of hormone therapy) and stratiﬁed
by time period.
bIncludes death from prostate cancer.
cIncludes death from any cause.
dFrom competing risks regression model, adjusted for stratiﬁcation factors at randomisation (except hospital and choice of hormone therapy) and time
period, and treating causes of death other than the focus as a competing event.
eCause attributed on central death review; prostate cancer death as event, other cause of death as competing event.
fCause attributed on central death review; other causes of death as event, prostate cancer as competing event.
Annals of Oncology Original article
Volume 29 | Issue 5 | 2018 doi:10.1093/annonc/mdy072 | 1241
Discussion
We and others have previously shown a survival advantage for
adding docetaxel (with or without prednisolone/prednisone) and
for adding abiraterone acetate and prednisolone/prednisone, in
patients starting long-term hormone therapy for the first time [4–
11]. However, there is currently no direct evidence available to
help clinicians or patients assess which combination might be bet-
ter. Here, we reported a pre-specified (but not pre-powered) ana-
lysis using only patients who were randomised during a period of
the study when recruitment to the two research arms overlapped.
We used data collected prospectively from over 100 sites across
two countries as part of a clinical trial protocol. The MAMS plat-
form design of STAMPEDE, an approach sometimes referred to as
a master protocol [16], facilitated this comparison. Separate, trad-
itional, two-arm RCTs, would not have allowed any directly rand-
omised comparative evidence to be available so soon.
Our recently reported overall treatment effect on survival, in
STAMPEDE, for adding AAP compared with the SOC
(HR¼ 0.63) [10] was larger than the previously-reported overall
treatment effect, in STAMPEDE, on survival for adding DocP to
the same SOC (HR¼ 0.78) [7]. The earlier secondary efficacy OMs
favoured adding AAP over DocP, including FFS—perhaps unsur-
prising given the direct antiandrogenic action of AAP (around
four in every five FFS events was driven only by a rise in PSA) and
PFS (which excludes rising PSA). There was weak evidence favour-
ing AAP for MPFS and no evidence of a difference in symptomatic
skeletal events, prostate cancer-specific survival or OS.
Comparing the results indirectly of these two therapies by read-
ers extracting data from STAMPEDE’s AAP and docetaxel papers
[7, 10] may not be the most appropriate way to compare the rela-
tive effectiveness: the patient cohorts were all not randomised con-
temporaneously and there may be confounding biases when
comparing the two datasets, in particular, many DocP patients had
very limited salvage CRPC options compared with AAP patients,
simply due to the timing of licences of new therapies (see below).
Importantly, the two therapies are being used in different ways.
AAP is used until the patient has castrate-resistant prostate can-
cer (CRPC), often lasting many years and consequently exhaust-
ing a major therapy option for CRPC. In contrast, DocP is given
as an 18-week course thus all CRPC options should remain avail-
able. Our data reveal important differences in the pattern of treat-
ment failure yet we do not see any differences in survival,
suggesting that the relative time spent before and after first-line
treatment failure are quite different by initial treatment. This may
explain why the early, often biochemically driven OMs, favour
AAP but the later post CRPC end points such as skeletal events,
prostate cancer-specific survival and OS show no good evidence
of a difference. Men receiving DocP will thus spend longer with
CRPC than men receiving AAP but with a broader range of more
effective options available. Supplementary Figure S1, available at
Favours
SOC+AAP
Failure-free
survival
Progression-free
survival
Symptomatic skeletal
events
Cause-specific
survival
Overall survival
0.5 1.0 2.0
Hazard ratio
Metastatic
progression-free
survival
Favours
SOC+DocP
Figure 4. Depiction of disease state over time.
Table 3. Worst adverse event (grade) reported over entire time on trial
SOC1Doc
(n5 189)
SOC1AAP
(n5 377)
Safety population
Number of patients included in analysisa 172 373
Patients with an adverse event—no. (%)
Grade 1–5 adverse event 172 (100) 370 (99)
Grade 3–5 adverse event 86 (50) 180 (48)
Grade 3–5 adverse events—no. (%)
Endocrine disorder 15 (9) 49 (13)
Febrile neutropenia 29 (17) 3 (1)
Neutropenia (neutrophils) 22 (13) 4 (1)
General disorder 18 (10) 21 (6)
Fatigue 7 (4) 8 (2)
Oedema 1 (1) 2 (1)
Musculoskeletal disorder 9 (5) 33 (9)
Cardiovascular disorder 6 (3) 32 (9)
Hypertension 0 (0) 12 (3)
Myocardial infarction 2 (1) 4 (1)
Cardiac dysrhythmia 1 (1) 5 (1)
Gastrointestinal disorder 9 (5) 28 (8)
Hepatic disorder 1 (1) 32 (9)
Increased AST 0 (0) 6 (2)
Increased ALT 1 (1) 23 (6)
Respiratory disorder 12 (7) 11 (3)
Dyspnoea 4 (2) 1 (1)
Renal disorder 5 (3) 20 (5)
Lab abnormalities 9 (5) 11 (3)
Hypokalaemia 0 (0) 3 (1)
aThe safety population includes patients who started their allocated
treatment.
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Annals of Oncology online, shows the status of all patients at each
moment in time after randomisation. That the DocP cohort had
more durable survival after failure, perhaps longer than before
failure, may be important in counselling patients’ biochemically
failing after DocP.
The number of events is an important consideration in time-
to-event analyses. The number of patients with metastases at
baseline was balanced by arm, but, particularly because of their
poorer prognosis, these patients tend to predominate in this ana-
lysis. There is no evidence of heterogeneity in the treatment effect
by baseline metastasis for any of the OMs, but power to detect
any heterogeneity is very limited, especially in later OMs with
fewer events.
The patterns of toxicity are quite different for the two treat-
ment approaches, consistent with the known effects of the drugs.
The proportion of patients reporting at least one grade 3 or worse
toxicity was similar and in line with previously reported toxicities
for these agents (Table 3). In patients who started their allocated
treatment and who are without disease progression at 1 year, the
prevalence of grade 3 or worse toxicity was about 11% on both
arms and very similar to our previous estimate for SOC. Nearly
all patients started their allocated abiraterone, whereas about 1 in
12 patients did not start their allocated docetaxel. Our results
may change future compliance with both treatments in routine
practice; but the lack of compliance with allocated treatment of
docetaxel is likely to have had some impact on our estimated ef-
fect sizes.
A key limitation is that the comparison was opportunistic and
not designed in the usual way, hence power is limited to detect
any realistic differences. The trigger for the analysis was the re-
porting of our ‘abiraterone comparison’ data [10]. The unequal
allocation ratio reflects the planned design of the comparisons.
The allocated treatment being given was not masked for practical
reasons. This, of course, allowed for relapse therapies to be given
at the investigator’s discretion. We observed that after relapse,
many patients received the treatment class that they had not
received up-front.
Salvage options have changed over time: men recruited earlier
on to DocP (2005–2013) will have had very different options to
those recruited later to AAP (2011–2014) when there were more
CRPC therapies likely available, including AAP [17, 18], cabazi-
taxel [19], docetaxel [20, 21], enzalutamide [22, 23], radium-223
[24] and sipuleucel-T [25] (although not widely accessible in
Europe). For this analysis, we limited ourselves to patients con-
temporaneously randomised to either arm to make this compari-
son as fair as possible. However, FFS events generally happened
sooner with DocP than with AAP in time from randomisation
and, therefore, calendar year (Table 4) may partially influence
outcomes. Furthermore, a FFS event was more of an indication to
change treatments on DocP; AAP continued beyond this point.
As far as we are aware there are no ongoing randomised trials
directly comparing adding AAP versus adding docetaxel for
patients starting long-term ADT. All of our published
STAMPEDE data have contributed to the STOpCaP aggregate
data network meta-analysis that has used all of the reported
RCTs in metastatic patients to perform indirect comparisons
and allow some assessment of potential ranking of effective
therapies. This aggregate data analysis (co-submitted) will be
supplemented by a forthcoming individual patient data (IPD)
network meta-analysis which will hopefully provide a more
accurate reflection of the temporal interval between the applica-
tion of the two different therapies, to which STAMPEDE will
contribute all relevant data. We will continue to follow-up pa-
tients for long-term OMs.
Considering their mechanisms of action and their proven
oncological benefits, the question is raised of whether a combin-
ation of AAP plus docetaxel might lead to an approximately addi-
tive benefit of using them both, further extending survival.
Randomised data on docetaxel with or without abiraterone will
emerge from a subset the PEACE-1 trial (https://clinicaltrials.
gov/ct2/show/NCT01957436), as will non-randomised, time-
stratified data on abiraterone with or without docetaxel.
Similarly comparative data will also emerge for enzalutamide, an-
other AR-targeted therapy, from the ENZAMET trial (https://clin
icaltrials.gov/ct2/show/NCT02446405) and with the combin-
ation of enzalutamide and AAP in STAMPEDE (Figure 1).
In conclusion, there are now two systemic therapies, DocP and
AAP, which have shown a survival benefit from RCTs when
added to treatment of patients starting long-term ADT for the
first time. The evidence from our directly randomised data com-
paring these two therapies showed no evidence of a difference in
overall or prostate cancer-specific survival, nor in other import-
ant outcomes such as symptomatic skeletal events, suggesting
that both currently remain viable new standards-of-care.
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